Related Experiment Video
Updated: Feb 11, 2026

Reconstitution Of β-catenin Degradation In Xenopus Egg Extract
Published on: June 17, 2014
TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway
Ilaria Grazia Zizzari1, Chiara Napoletano2, Andrea Botticelli3
1Laboratory of Tumor Immunology and Cell Therapy, Department of Experimental Medicine, Policlinico Umberto I, "Sapienza" University of Rome, Rome, Italy. ilaria.zizzari@uniroma1.it.
Abstract:
Tyrosine kinase inhibitors (TKIs) target angiogenesis by affecting, for example, the VEGF receptors in tumors and have improved outcomes for patients with metastatic renal cell carcinoma (mRCC). Immune checkpoint inhibitors (ICIs) have also been proposed for treatment of mRCC with encouraging results. A better understanding of the activity of immune cells in mRCC, the immunomodulatory effects of TKIs, and the characteristics defining patients most likely to benefit from various therapies will help optimize immunotherapeutic approaches. In this study, we investigated the influence of the TKI pazopanib on dendritic cell (DC) performance and immune priming. Pazopanib improved DC differentiation and performance by promoting upregulation of the maturation markers HLA-DR, CD40, and CCR7; decreasing IL10 production and endocytosis; and increasing T-cell proliferation. PD-L1 expression was also downregulated. Our results demonstrate that pazopanib inhibits the Erk/β-catenin pathway, suggesting this pathway might be involved in increased DC activation. Similar results were confirmed in DCs differentiated from mRCC patients during pazopanib treatment. In treated patients pazopanib appeared to enhance a circulating CD4+ T-cell population that expresses CD137 (4-1BB). These results suggest that a potentially exploitable immunomodulatory effect induced by pazopanib could improve responses of patients with mRCC in customized protocols combining TKIs with ICI immunotherapy. Cancer Immunol Res; 6(6); 711-22. ©2018 AACR.
Insights
Pazopanib, a tyrosine kinase inhibitor, enhances dendritic cell function and T-cell proliferation in metastatic renal cell carcinoma (mRCC) patients. This suggests pazopanib may improve responses when combined with immune checkpoint inhibitors.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) treatment has improved with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs).
- Understanding TKI immunomodulatory effects and patient selection is crucial for optimizing immunotherapy in mRCC.
Purpose of the Study:
- To investigate the impact of the TKI pazopanib on dendritic cell (DC) performance and immune priming in mRCC.
- To explore the underlying mechanisms of pazopanib's effects on DCs and T-cells.
Main Methods:
- Assessed DC differentiation, maturation markers (HLA-DR, CD40, CCR7), IL10 production, endocytosis, and T-cell proliferation.
- Investigated the effect of pazopanib on the Erk/β-catenin pathway and PD-L1 expression.
- Confirmed findings in DCs from mRCC patients undergoing pazopanib treatment.
Main Results:
- Pazopanib improved DC differentiation and performance, increasing maturation markers and T-cell proliferation while decreasing IL10 and endocytosis.
- Pazopanib downregulated PD-L1 expression and inhibited the Erk/β-catenin pathway.
- Pazopanib enhanced circulating CD4+ T-cells expressing CD137 (4-1BB) in treated mRCC patients.
Conclusions:
- Pazopanib exhibits immunomodulatory effects that enhance DC activation and T-cell responses.
- The Erk/β-catenin pathway may mediate pazopanib-induced DC activation.
- Pazopanib holds potential for combination therapy with ICIs to improve outcomes in mRCC.
More Related Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Related Concept Videos
TGF - β Signaling Pathway
Catenins
Catenins in Cell Junctions
Catenins bind to cell adhesion molecules such as cadherins and link them to different cytoskeletal proteins depending on the type of cell junction. At the...
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Other Glycolytic Pathways